FARON PHARMACEUTICALS OY Logo

FARON PHARMACEUTICALS OY

Clinical-stage biopharmaceutical company developing immunotherapies for cancer.

FARN | IL

Overview

Corporate Details

ISIN(s):
FI4000153309
LEI:
7437009H31TO1DC0EB42
Country:
Finland
Address:
Joukahaisenkatu 6, FI-20520 TURKU

Description

Faron Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative immunotherapies for cancer. The company pioneers macrophage-targeting therapies to leverage the patient's immune system, aiming to address unmet medical needs and improve outcomes. Its lead asset, bexmarilimab, is a first-in-class anti-Clever-1 antibody and a myeloid cell-targeting immunotherapy candidate. Bexmarilimab is being investigated in clinical trials as a potential therapy for hematological malignancies and solid tumors, often in combination with standard-of-care treatments.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2024-08-07 11:00
Grant of options
English 42.3 KB
2024-08-06 09:30
Faron Appoints Dr. Petri Bono as new CMO
English 17.9 KB
2024-07-11 08:00
Faron Announces Positive FDA Feedback
English 22.6 KB
2024-06-25 15:00
Update on settlement
English 21.4 KB
2024-06-25 11:30
Holding(s) in Company - Replacement
English 54.3 KB
2024-06-24 13:45
Holding(s) in Company
English 52.7 KB
2024-06-20 14:00
New shares registered with Finnish Trade Register
English 23.4 KB
2024-06-20 08:00
Fully subscribed EUR 30.7 million share offering
English 94.5 KB
2024-06-05 09:00
Proposed REX Retail Offer
English 37.7 KB
2024-06-04 08:00
Faron commences a share offering
English 108.6 KB
2024-05-20 08:00
Initial positive data from Phase 2 of BEXMAB
English 20.7 KB
2024-05-17 17:00
Issuance of warrants
English 11.4 KB
2024-05-16 08:05
Founders named European Inventor Award finalists
English 18.2 KB
2024-05-13 08:00
Replacement – Board Change
English 17.6 KB
2024-04-30 15:00
Update on financial status
English 13.8 KB

Automate Your Workflow. Get a real-time feed of all FARON PHARMACEUTICALS OY filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for FARON PHARMACEUTICALS OY

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for FARON PHARMACEUTICALS OY via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.